Robert S. Negrin

Medicine · Health Sciences

84h-index25.9kcitations631works3.72yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Hematopoietic Stem Cell Transplantation(248), Immune Cell Function and Interaction(227), CAR-T cell therapy research(200), T-cell and B-cell Immunology(176), Immunotherapy and Immune Responses(99)

Publications629 total

Characterization and Outcomes of Switching Tacrolimus to Sirolimus in Patients with Transplant-Associated Thrombotic Microangiopathy
Transplantation and Cellular Therapy·2026
Orca-T versus allogeneic hematopoietic stem cell transplantation (PRECISION-T): a multicenter, randomized phase 3 trial
Blood·2025· 1 citedOpen Access
Off-the-shelf CD117 CAR-iNKT cells as a safe and effective allogeneic immunotherapy targeting AML and its immunosuppressive microenvironment
Blood·2025
Post-transplant cyclophosphamide vs tacrolimus/methotrexate: Improved GRFS, reduced NRM, and less severe GVHD in myeloablative HLA-matched allogeneic transplantation
Blood·2025Open Access
CD22-directed CAR-T cells induce complete remissions in high-risk follicular and Mantle Cell Lymphoma with limited neurotoxicity
Blood·2025Open Access
Targeting CD117 with engineered invariant natural killer T cells (iNKT Cells) as a novel approach for acute myeloid leukemia treatment
Blood·2025
Allogeneic HSC and regulatory T cell  (Orca-T) engineered cell therapy following reduced intensity conditioning: Results of a single center Phase 1 study
Blood·2025
Orca-T improves chronic graph-versus-host disease free in patients with a broad range of demographic and clinical variables: Results of randomized, Phase 3 trial
Blood·2025Open Access
Double-dose axicabtagene ciloleucel (Axi-Cel-2) as second-line therapy for high-risk relapsed or refractory large B-cell lymphoma (r/rLBCL): Interim results from a Phase 1b study
Blood·2025Open Access
Inhibition of DRP1–FIS1–Mediated mitochondrial fission as a novel strategy to prevent gvhd
Blood·2025Open Access
Patients with TP53-mutated AML/MDS without complex or monosomal karyotype can achieve durable survival benefits with allogeneic HCT
Blood·2025Open Access
Superior efficacy and persistence of Orca-T-allogeneic CAR19/22 versus autologous CAR19/22 in high-risk adult B-ALL
Blood·2025Open Access
Evaluating thymic stromal lymphopoietin (TSLP) as a biomarker in acute graft versus host disease
Blood·2025Open Access
Regulatory T cell approaches for graft-versus-host disease prevention
Current Opinion in Immunology·2025Open Access
CAR19 therapy drives expansion of clonal hematopoiesis and associated cytopenias
2025Open Access
POSTER: CT-262 A Randomized Phase 3 Trial in Patients with Hematologic Malignancies Demonstrates Improved Survival Free of Chronic GVHD with Orca-T® Compared to Conventional Allogeneic Hematopoietic Stem Cell Transplant
Clinical Lymphoma Myeloma & Leukemia·2025
CT-262: A Randomized Phase 3 Trial in Patients with Hematologic Malignancies Demonstrates Improved Survival Free of Chronic GVHD with Orca-T® Compared to Conventional Allogeneic Hematopoietic Stem Cell Transplant
Clinical Lymphoma Myeloma & Leukemia·2025
Fatal recurrence of IEC-HS after autologous stem cell boost in patients receiving BCMA-CAR T-cell therapy
Blood Advances·2025· 2 citedOpen Access
Single-cell transcriptomic profiling reveals diversity in human iNKT cells across hematologic tissues
Cell Reports·2025· 5 citedOpen Access
Observational Comparison of Overall Survival between Phase 1b Orca-T and Registry-Based Post-Transplant Cyclophosphamide Patients
Transplantation and Cellular Therapy·2025· 1 cited
page 1 of 32Next →

Frequent Co-authors

Christopher H. Contag(12), Karl G. Blume(8), Andreas Beilhack(8), Matthias Edinger(7), Laura Johnston(7), Judith A. Shizuru(7), Robert Lowsky(5), Robert Zeiser(5), Jeanette Baker(5), Michael H. Bachmann(5), Irving L. Weissman(5), Samuel Strober(4), Sally Arai(4), Everett Meyer(4), David B. Miklos(4), Dennis B. Leveson-Gower(4), Michael R. Verneris(4), Jeanette Baker(4), Richard T. Hoppe(4), Wen‐Kai Weng(3)